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Authors reply:  
We thank the authors Braillon and Bewley for taking the time to respond to some of the 
issues raised in our article. [1]. 
 
In terms of a response, we must emphasise that the CPIT trial on which the economic 
evaluation was based was a phase II trial, in which the primary objective was to explore 
therapeutic efficacy in patients. Also, the objective of the economic evaluation was to assess 
the cost-effectiveness of the addition of financial incentives to services as usual, not as an 
alternative to existing stop smoking services.    
 
We will now address each of the comments by Braillon and Bewley in turn.  
 
• Boyd et al’s conclusion that financial incentives (FI) for smoking cessation in deprived 
pregnant women “are highly cost-effective” is highly questionable when extrapolating 
short term cessation to life-time analysis.  
 
As detailed in the results table of our manuscript [1] the probabilistic sensitivity analysis – 
which formally assesses the uncertainty in the lifetime model [2] – found a 72% probability 
that the addition of financial incentives will be cost-effective (only a 28% probability that 
they are not cost-effective).  The paper also explicitly addresses issues with the lifetime 
extrapolation, particularly uncertainty in relapse rates post birth, and formally explored this 
using probabilistic analysis on a range of scenarios to explore alternative assumptions in the 
lifetime extrapolation [1]. These scenario analyses again found the incentives arm to be the 
cost-effective option over a range of alternative model assumptions.  
  
• The original phase II randomised controlled trial has several limitations: 
a. The control group had a higher Fagerstrom score for all items  
 
As detailed in the CPIT trial paper [3] correction and control for the Fagerstrom score made 
no difference to the final results. 
 
b. FIs improve retention rates and patients might be more circumspect with the 
truth.  False reporting of smoking status may be low when both saliva and urine 
cotinine are systematically monitored but is more likely in this study which used 
self report or exhaled carbon monoxide before giving participants £400. 
 
The trial primary outcome is the important issue (cotinine validated self-report of smoking 
near the end of pregnancy). The primary outcome used self-report on the telephone, 
followed by carbon monoxide and salivary cotinine validation, both of which had to be 
negative for quit to be confirmed. However it should be made clear that to receive 
payments a home visit had to succeed in collecting a carbon monoxide breath test which 
had to be negative and at the same time a saliva was collected for cotinine. So no payments 
were given at the primary outcome point near the end of pregnancy unless all samples were 
available for analysis.  
 
In the FI group: 30 intervention were never contactable for validation vs 23 controls;  
 
These patients were never designated for confirmation by carbon monoxide breath test and 
cotinine. Only 2 residual samples from the last 10 weeks of pregnancy were available from 
these participant both from the intervention group. Both samples indicated current 
smoking. 
 
among 18 tested during routine care and considered as quitters (selfreport), four had 
blood cotinine levels indicating they were smoking. 
 
This statement is not correct (3). 
 
 
c. The authors considered patients who were lost to follow-up had continued to 
smoke. This will overestimate positive results 
 
First, for 46 participants in the incentives group, contact could not be made at 34-38 weeks’ 
gestation after multiple attempts, initially by the helpline and then by research nurses after 
contact checks. Ten had residual blood samples available, taken for other purposes in the 
last 10 weeks of pregnancy, and all 10 samples indicated current smoking when tested for 
cotinine. Similarly, three residual samples were available from 43 control participants, and 
all indicated current smoking.[3] Participants lost to follow-up were therefore examined 
using residual routine blood samples from late pregnancy assayed for cotinine, and all 
tested in both intervention and control groups were smokers. 
 
 
• Additionally the treatment was inadequate 
a. Both groups only received a single form of nicotine replacement therapy (NRT), at 
an inadequate dose (16 mg/24h). Smoking cessation rates in pregnant women 
are reported as 16% without medication and 36% with a combination of various 
forms of NRT. A single form of NRT at 16 mg/24h alone has shown no benefit. 
Combining patches with faster acting forms of NRT (a ‘belt and braces’ strategy) 
works substantially better than patches alone in all populations. As pregnancy 
increases nicotine metabolism, remembering the basic pharmacological principle 
of dose response effect is crucial. 
 
The two substantive trials of nicotine replacement therapy in pregnancy have shown no 
significant improvement in quit rate compared with placebo [4, 5].  The latter used current 
first line treatment available in the UK NHS. 
 
b. Phone calls can hardly replace face-to-face visits for psychological therapy, 
particularly in the deprived. 
 
This issue relating to motivational interviewing has already been discussed by ourselves and 
the responders in rapid responses to the main paper describing the CPIT trial[3] (Tappin D, 
Bauld L, Purves D et al. Financial incentives for smoking cessation in pregnancy: randomised 
controlled trial. BMJ 2015 27;350:h134) 
 
• The Markov design to extrapolate short term cessation to life-time is inadequate.   
 
The Markov model design used to extrapolate short term cessation rates was appropriate 
for lifetime modelling of smoking cessation interventions, and additionally the approach 
used adhered to good practice modelling guidelines and the NICE reference case [6-8]. In 
economic evaluation modelling is required to extrapolate short term results over a patient 
lifetime to help make an informed decision based on currently available evidence [8; 9].  
There are always issues regarding uncertainty in extrapolation and therefore, in line with 
best practice, probabilistic sensitivity analysis was undertaken on both the base case model 
and scenario analyses [2; 10] to explore and capture this uncertainty in both 95% confidence 
intervals, and then present the likelihood of being the cost-effective option in a cost-
effectiveness acceptability assessment [11].  
 
• While FIs appear to increase attempts to quit and short term treatment use, smoking 
cessation rates show only small absolute increases at best. Long term quit rates are not 
improved.  
 
There is growing evidence to question these statements [12]. Additionally, in the base case 
model we drew evidence from a wide range of existing literature to inform parameters on 
relapse post birth and long term cessation [13-17]. A recent English study provided 
biochemically verified quit and relapses at 6 months postpartum [18]. 
 
• This is unsurprising as FIs do not promote autonomy 
Practical autonomy is questionable when you ‘have to’ receive a psychological intervention 
because you provided the perceived expected response at your maternity booking 
appointment that you wanted to quit smoking, when in fact you had not even thought 
about smoking cessation. The offer of a financial incentive to think about smoking and 
cessation and to engage with services gives much greater self governance and autonomy to 
people who are used to being told what to do by health professionals. Then if you quit and 
realise the fruits of self governance by spending the ‘love-to-shop’ vouchers on yourself or 
your loved ones you start to achieve true autonomy. Continued cessation provides direct 
improvement in living standards by not having to spend at least £10 per day on cigarettes.  
 
Lastly, the approach is far from fair. The most socially deprived citizens deserve better living 
conditions, an intervention which does work.   
 
This statement is the authors opinion and is irrelevant to the question at hand which is 
regarding efficient spending of public money to improve smoking cessation amongst 
pregnant women for the health of themselves and their babies.  Financial incentives have 
been proposed as a valuable addition to the behaviour change toolkit [19; 20], with a wide 
body of experimental evidence supporting their success in abstinence from a range of 
addictive substances (19-25) and also in the areas of education and obesity [20;24;26].  
 
Braillon and Bewley conclude that “Maybe spending £400 more to train practitioners to do 
their jobs properly in the first place would be more ethical and cost effective than FIs”.  This 
is the authors conjecture and not based on any evidence or an economic evaluation.  It is 
important to understand that the objective of the economic evaluation was to explore the 
cost-effectiveness of the addition of financial incentives to services as usual, not as an 
alternative to existing stop smoking services.  Current stop smoking services supported by 
the UK NHS are both effective and cost-effective[27;28]and include practitioner and GP 
advice, pharmacists and smoking cessation specialists face to face support, group therapy 
and telephone support [27]. A range of effective cessation services exist to support 
pregnant smokers, however, getting pregnant women to engage with cessation services and 
undertake a successful quit attempt has proved difficult nationally and internationally. Our 
study shows that financial incentives could also be a potentially cost-effective tool in 
addition to the stop smoking services [1]. 
We do however agree that the case for implementing financial incentives across the NHS is 
far from proved, and that a phase III definitive trial and economic evaluation of financial 
incentives to support smoking cessation during pregnancy should be carried out in the UK. It 
is important that such a trial also collects evidence on biochemically validated quit post 
birth. Financial incentives are potentially a highly cost effective intervention to help 
pregnant smokers stop and to improve the health and wealth of the poorest in our society. 
It is important that this potentially highly effective health promoting intervention is not lost 
in a haze of political rhetoric and poor science.  
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